Gemfibrozil treatment increases low-dens
✍
O’Neal, D.N.; O’Brien, R.C.; Timmins, K.L.; Grieve, G.D.; Lau, K.P.; Nicholson,
📂
Article
📅
1998
🏛
John Wiley and Sons
🌐
English
⚖ 115 KB
The aim of this study was to determine the effect of the lipid modifying agent gemfibrozil on lipid and coagulation risk factors in patients with Type 2 diabetes mellitus (Type 2 DM). Twenty-six subjects with Type 2 DM and dyslipidaemia were treated for 24 weeks with either gemfibrozil 600 mg orally